Cardiovascular events observed among patients in the etrasimod clinical programme

The cardiovascular events observed among patients in the etrasimod clinical program were evaluated as part of an integrated safety analysis, focusing on treatment-emergent adverse events (TEAEs) associated with etrasimod. Here are the detailed findings:

1. Bradycardia:

• Bradycardia (slower than normal heart rate) occurred more commonly in patients treated with etrasimod compared to placebo.
• These events were generally mild or moderate in severity.
• Bradycardia was most often observed on the first day of treatment initiation.
• The events were transient and typically resolved without requiring medical intervention.
• Serious conduction abnormalities related to bradycardia were rare.

2. Atrioventricular (AV) Block:

• AV block (a type of heart block affecting electrical conduction between the heart's chambers) was also more frequent in the etrasimod group.
• Similar to bradycardia, these events were mild or moderate, transient, and primarily occurred shortly after starting treatment.
• Serious AV block events were rare.

3. Hypertension:

• Hypertension-related events (elevated blood pressure) were slightly more common with etrasimod than with placebo.
• These events were generally manageable and classified as non-serious.
• Hypertension-related events did not lead to treatment discontinuation.

4. Major Cardiovascular Events (CAD and CVD):

• The analysis also monitored for major cardiovascular events such as coronary artery disease (CAD) and cerebrovascular disease (CVD).
• The incidence rates of CAD and CVD were very low across all study cohorts, including both etrasimod-treated and placebo groups.

Summary of Cardiovascular Safety:

• Overall, cardiovascular-related TEAEs were infrequent in the etrasimod clinical program.
• Most events were mild to moderate, transient, and resolved without intervention.
• Serious cardiovascular events, including conduction abnormalities, were rare.
• The results suggest that etrasimod has a favorable cardiovascular safety profile in patients with moderately to severely active ulcerative colitis.

Conclusion:

The study supports the continued use of etrasimod in this patient population, with appropriate clinical monitoring to manage cardiovascular risks, particularly during the initial stages of treatment.